Zobrazeno 1 - 10 of 57 pro vyhledávání: '"David Piontkowsky"'
1
Akademický článek
Efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in Asian participants with human immunodeficiency virus 1 infection: A sub-analysis of phase 3 clinical trials
Autor: Yeon-Sook Kim, Shinichi Oka, Ploenchan Chetchotisakd, Amanda Clarke, Khuanchai Supparatpinyo, Anchalee Avihingsanon, Winai Ratanasuwan, Sasisopin Kiertiburanakul, Kiat Ruxrungtham, SangYoun Yang, Susan Guo, YaPei Liu, Moupali Das, Do Tran, Damian McColl, Roberto Corales, Chris Nguyen, David Piontkowsky
Publikováno v: HIV Research & Clinical Practice, Vol 20, Iss 3, Pp 73-81 (2019)
Background: The efficacy and safety of a single tablet regimen (STR) of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) was analyzed in Phase 3 clinical trials in antiretroviral therapy (ART)-naive and ART-experienced Asian pa
Externí odkaz: https://doaj.org/article/711e6e6e50dd4b56a9d28b36f8f97686
Zobrazit plný text záznamu
2
Akademický článek
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens.
Autor: Gregory D Huhn, Moti Ramgopal, Mamta K Jain, Federico Hinestrosa, David M Asmuth, Jihad Slim, Deborah Goldstein, Shauna Applin, Julie H Ryu, Shuping Jiang, Stephanie Cox, Moupali Das, Thai Nguyen-Cleary, David Piontkowsky, Bill Guyer, Lorenzo Rossaro, Richard H Haubrich
Publikováno v: PLoS ONE, Vol 15, Iss 1, p e0224875 (2020)
IntroductionGuidelines advocate the treatment of HCV in all HIV/HCV co-infected individuals. The aim of this randomized, open-label study (ClinicalTrials.gov identifier: NCT02707601; https://clinicaltrials.gov/ct2/show/NCT02707601) was to evaluate th
Externí odkaz: https://doaj.org/article/17f99115a1574511a445b8925d582138
Zobrazit plný text záznamu
5
Akademický článek
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
Autor: Josep M Llibre, François Raffi, Graeme Moyle, Georg Behrens, Stephane Bouee, Geraldine Reilly, Peter Borg, David Piontkowsky, Felipe Rogatto
Publikováno v: PLoS ONE, Vol 11, Iss 5, p e0155406 (2016)
OBJECTIVES:The objective of this analysis is to perform an indirect comparison of elvitegravir, cobicistat, emtricitabine and tenofovir DF (E/C/F/TDF) to abacavir/lamivudine and dolutegravir (ABC/3TC + DTG) by using 2 trials evaluating each of these
Externí odkaz: https://doaj.org/article/5675cfcf33db412abc99cc1339a26148
Zobrazit plný text záznamu
7
Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial
Autor: Moupali Das, Federico Pulido, Ian R. McNicholl, Maria Gracia Mateo-Garcia, Edmund Ong, Franco Maggiolo, Giuliano Rizzardini, Yongwu Shao, François Raffi, Richard Haubrich, Jean-Michel Molina, David Piontkowsky
Publikováno v: Lancet HIV
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Background Tenofovir alafenamide is associated with less renal and bone toxicity than tenofovir disoproxil fumarate and might improve the long-term safety of antiretroviral therapy. We aimed to investigate the effect on bone mineral density of switch
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::51f2c7c9469b68fe0ef30fa6ea2ccf5e
https://doi.org/10.1016/s2352-3018(19)30195-x
Zobrazit plný text záznamu
8
Switching to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in Adults With HIV and M184V/I Mutation
Autor: Yongwu Shao, Ian R. McNicholl, Lauren Temme, Stefan Esser, Ignacio Pérez-Valero, Richard Haubrich, Antonella Castagna, David Piontkowsky, Nicolas A. Margot, Jean-Michel Molina, Federico Pulido, Josep M. Llibre
Publikováno v: Journal of Acquired Immune Deficiency Syndromes (1999)
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
instname
Background: The ability of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) to maintain virologic suppression in participants with M184V and/or M184I resistance mutations from historical genotypic reports when switching from a
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22332dfa9396532cdc87534152e7cbd5
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85102222221
Zobrazit plný text záznamu
9
HIV/HCV therapy with ledipasvir/sofosbuvir after randomized switch to emtricitabine-tenofovir alafenamide-based single-tablet regimens
Autor: Mamta K. Jain, Deborah Goldstein, Julie H. Ryu, Thai Nguyen-Cleary, Shuping Jiang, Shauna Applin, Stephanie Cox, Moupali Das, Lorenzo Rossaro, Jihad Slim, Gregory D Huhn, Federico Hinestrosa, Moti Ramgopal, David M. Asmuth, Bill Guyer, Richard Haubrich, David Piontkowsky
Publikováno v: PLoS ONE
PLoS ONE, Vol 15, Iss 1, p e0224875 (2020)
IntroductionGuidelines advocate the treatment of HCV in all HIV/HCV co-infected individuals. The aim of this randomized, open-label study (ClinicalTrials.gov identifier: NCT02707601; https://clinicaltrials.gov/ct2/show/NCT02707601) was to evaluate th
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0d53f77a18718555e67c85870112bc30
http://europepmc.org/articles/PMC6988963
Zobrazit plný text záznamu
10
Virological Outcomes of EVG/COBI/FTC/TDF and EVG/COBI/FTC/TAF in Antiretroviral-Naive HIV-1-Infected Participants with Baseline HIV-1 RNA ≥1,000,000 Copies/ml: A Post Hoc Analysis of Phase III Clinical Trials
Autor: Kirsten L. White, Damian J McColl, Edwin DeJesus, Christian Callebaut, David Piontkowsky, Hui Wang, Martin S. Rhee, Paul E. Sax, Jennifer Demorin, Erin Quirk, Moupali Das, David A. Wohl, Calvin J. Cohen
Publikováno v: Antiviral Therapy. 23:95-99
We address a data gap identified by Adams et al., of virological efficacy outcomes and emergent drug resistance in HIV-1-infected, antiretroviral treatment (ART)-naive participants with baseline (BL) viral loads (VL) >1,000,000 copies/ml. Initial ART
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9664868d3f15e46847fb12e76282b76
https://doi.org/10.3851/imp3187
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje